Background Concomitant administration of erlotinib with standard chemotherapy does not
appear to improve survival among patients with non-small-cell lung cancer (NSCLC), but …

以吉非替尼, 厄洛替尼为代表的表皮生长因子受体酪氨酸激酶抑制剂(EGFR-TKI)
广泛用于非小细胞肺癌的治疗. 但随着EGFR-TKI 的不断应用, 肿瘤细胞对药物的敏感性逐渐 …

Background: In recent years, reduction of nuclear power generation and the use of coal-fired
power for filling the power supply gap might have increased the risk of lung cancer. This …

Background. Pharmaco-dynamic separation of cytotoxic and targeted drugs might avoid
their mutual antagonistic effect in the treatment of advanced non-small cell lung cancer …

Preclinical studies have suggested that combining cytotoxic agents with epidermal growth
factor receptor tyrosine kinase inhibitors (EGFR‐TKIs) to treat EGFR‐mutated tumors may …

The purpose of this study was to determine whether docetaxel increases the risk of severe
infections in patients with non-small cell lung cancer. A thorough literature search of the …

Objectives Head and neck squamous cell carcinoma (HNSCC) is characterized by high
mortality and low survival rates. As an epidermal growth factor receptor (EGFR) inhibitor …

Purpose Erlotinib is active in advanced non-small cell lung cancer (aNSCLC) particularly in
patients with EGFR-sensitizing mutations. The thymidylate synthase inhibitors are active in …

Introduction The purpose of this study was to assess whether an intercalated dosing
schedule of erlotinib and docetaxel could avoid possible negative interactions and optimize …

Introduction: Preclinical data showed that intercalated administration of epidermal growth
factor receptor-tyrosine kinase inhibitors (EGFR-TKIs) and chemotherapy might be effective …